Sorrento to Take Action Against Hindenburg Research for Statements Believed Intended to Manipulate Stock Price
August 12, 2020 19:51 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today that it believes it has uncovered fraudulent attempts to manipulate the Company’s...
Yuhan Corp and Sorrento Therapeutics Announce Closing of a $40m USD Financing for Joint Venture ImmuneOncia to Support Advancement of Immuno-Oncology Program
February 12, 2019 07:00 ET
|
Sorrento Therapeutics, Inc.
SEOUL, South Korea and SAN DIEGO, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Yuhan Corporation (000100.KS; Yuhan) and Sorrento Therapeutics (Nasdaq: SRNE) announced today that ImmuneOncia, a joint venture...
Dr. Henry Ji to Participate In Financing Expert Panel at East/West CEO Conference
January 04, 2019 07:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today that Dr. Henry Ji, Chairman and CEO, will participate in the East/West CEO...
1st Patient Treated for Osteoarthritis Knee Pain in Sorrento Resiniferatoxin Phase 1B Trial Meets Both Safety and Efficacy Expectations
August 13, 2018 04:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that the first enrolled patient in the phase 1b study of its non-opioid, afferent nerve...